James Shehan, MD
Dermatology · Omaha, NENPI 1316041734
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,124 of the $3,172 with a category attached, or 67.0%. Pfizer accounts for 77.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $2,659 and has fallen 96.3% since, to $99 in 2025.
Across 41 payments — averaging $77.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novartis$119
- Johnson & Johnson$101
- Regeneron Healthcare Solutions, Inc.$100
- Genentech USA, Inc.$99
- Amgen$77
- plus $221 from 7 others
Across 6 payments — averaging $8024.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$19K
- Galderma Laboratories, L.p.$18K
- Pfizer$11K
What the payments were for
- Travel & lodging$2,12467%
- Food & beverage$96130%
- Education$883%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $2,456 |
| Novartis | 6 | $119 |
| Johnson & Johnson | 7 | $101 |
| Regeneron Healthcare Solutions, Inc. | 2 | $100 |
| Genentech USA, Inc. | 7 | $99 |
| Amgen | 4 | $77 |
| AbbVie | 4 | $70 |
| LEO Pharma Inc. | 2 | $55 |
| Misonix Inc | 1 | $25 |
| Galderma Laboratories, L.p. | 2 | $25 |
| Sanofi | 1 | $20 |
| Organon | 1 | $20 |
| Prugen, Inc. Pharmaceuticals | 1 | $5 |
How this compares
$3,172 in reported general payments places this provider in the 60th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 101 | $4,288 |
| Fluorouracil | 41 | $3,399 |
| Metronidazole | 47 | $2,362 |
| Ketoconazole | 132 | $1,733 |
| Acitretin | 13 | $1,477 |
| Triamcinolone Acetonide | 111 | $814 |
| Hydrocortisone | 145 | $810 |
| Clindamycin Phosphate | 38 | $680 |
| Minocycline Hcl | 20 | $549 |
| Halobetasol Propionate | 14 | $381 |
| ValacyclovirValacyclovir Hcl | 14 | $345 |
| MethotrexateMethotrexate Sodium | 17 | $289 |
| Mupirocin | 32 | $227 |
| Hydroxychloroquine Sulfate | 11 | $219 |
| Prednisone | 26 | $41 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Omaha
- Rachel PersonOmaha$98K
- Erin BarrettOmaha$96K
- Joel SchlessingerOmaha$89K
- Mathew DaveyOmaha$35K
- Gage RenschOmaha$11K
- Herschel StollerOmaha$10K
- Deirdre StolmeierOmaha$10K
- Melissa DarlingOmaha$10K
- Christopher HuerterOmaha$7K
- Tina KinsleyOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.